Engineering Iron Oxide Nanoparticles for Clinical Settings

Nanobiomedicine

Volumn 1, Issue , 2014, Pages

  Cortajarena, Aitziber L ^a   Ortega, Daniel ^a,b   Ocampo, Sandra M ^a   Gonzalez García, Alberto ^a   Couleaud, Pierre ^a   Miranda, Rodolfo ^a   Belda Iniesta, Cristobal ^a,c,d   Ayuso Sacido, Angel ^a,c  

^a INSTITUTO MADRILEÑO DE ESTUDIOS AVANZADOS EN NANOCIENCIA IMDEA NANOCIENCIA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Hospital de Madrid   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Drug Delivery; IONP; Iron Oxide Nanoparticles; Magnetic Hyperthermia; MRI; Nanomedicine; SPION; USPION; VSPION

Indexed keywords

EID: 85027989928     PISSN: None     EISSN: 18495435     Source Type: Journal    
DOI: 10.5772/58841     Document Type: Article

References (126)

1. Krishnan KM. Biomedical nanomagnetics: A spin through possibilities in imaging, diagnostics, and therapy. IEEE Trans. Magn. 46, 2523–2558 (2010).
2. Coey JMD. Magnetism and Magnetic Materials. Cambridge University Press. 2010.
3. Ling D, Hyeon T., Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small [Internet] 9(9–10), 1450–1466 (2013). Available from: http://dx.doi.org/10.1002/smll.201202111.
4. Baaziz W, Pichon BP, Fleutot S, Magnetic iron oxide nanoparticles: Reproducible tuning of the size and nanosized-dependent composition, defects, and spin canting. J. Phys. Chem. C. 118(7), 3795–3810. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84894560846&partnerID=40&md5=f738e89fe887bd8209d8a92fb3de1a7d. Accessed on 21 Jan 2014.
5. He Q, Yuan T, Yan X, One-pot synthesis of size-and morphology-controlled 1-D iron oxide nanochains with manipulated magnetic properties. Chem. Commun. 50(2), 201–203 (2014). Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84889034764&partnerID=40&md5=409176aec077443f92e6d731dd0437f7. Accessed on 23 Oct 2013.
6. Zhang L, Dong WF, Sun HB. Multifunctional superparamagnetic iron oxide nanoparticles: Design, synthesis and biomedical photonic applications. Nanoscale 5, 7664–7684 (2013).
7. Geraldes CF, Laurent S., Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol. Imaging 4(1), 1–23 (2009).
8. Puri IK, Ganguly R., Particle transport in therapeutic magnetic fields. Annual Review of Fluid Mechanics 46, 407–440 (2014).
9. Barry SE. Challenges in the development of magnetic particles for therapeutic applications. Int. J. Hyperth. 24(6), 451–466 (2008).
10. Shi W, Wang J, Fan X, Gao H., Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: Implications for uptake of nanoparticles in animal cells. Phys. Rev. E -Stat. Nonlinear, Soft Matter Phys. 78(6) (2008).
11. Li X., Size and shape effects on receptor-mediated endocytosis of nanoparticles. J. Appl. Phys. 111(2) (2012).
12. Guimarães AP. Principles of Nanomagnetism. NanoScience and Nanotechnology series, Springer. (2009).
13. Cowburn RP, Koltsov DK, Adeyeye AO, Welland ME, Tricker DM. Single-domain circular nanomagnets. Phys. Rev. Lett. 83, 1042–1045 (1999).
14. Aharoni A., The concept of single-domain particle. IEEE Trans. Magn. 27, 4775–4777 (1991).
15. Shi W, Wang J, Fan X, Gao H., Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: Implications for uptake of nanoparticles in animal cells. Phys. Rev. E -Stat. Nonlinear, Soft Matter Phys. 78(6) (2008).
16. Dasgupta S, Auth T, Gompper G., Shape and orientation matter for the cellular uptake of nonspherical particles. Nano Lett. 14(2), 687–693 (2014).
17. Gao H., Probing mechanical principles of cell-nanomaterial interactions. J. Mech. Phys. Solids. 62(1), 312–339 (2014).
18. Shi X, von dem Bussche A, Hurt RH, Kane AB, Gao H., Cell entry of one-dimensional nanomaterials occurs by tip recognition and rotation. Nat. Nano. 6(11), 714–719 (2011).
19. Toy R, Peiris PM, Ghaghada KB, Karathanasis E., Shaping cancer nanomedicine: The effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond.) 9(1), 121–134 (2014).
20. Tombácz E, Illés E, Majzik A, Hajdú A, Rideg N, Szekeres M., Ageing in the inorganic nanoworld: Example of magnetite nanoparticles in aqueous medium. Croat. Chem. Acta. 80, 503–515 (2007).
21. Kosmulski M., Chemical Properties of Material Surfaces. CRC Press. 2001.
22. Zhang Y, Yang M, Portney NG, Zeta potential: A surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed. Microdevices 10(2), 321–328 (2008).
23. Hunter RJ. Colloid Science: Zeta Potential in Colloid Science: Principles and Applications. Acadedmic Press. 1981.
24. Berry C, Wells S, Charles S CA. Dextran and albumin derivatised iron oxide nanoparticles: Influence on fibroblasts in vitro. Biomaterials 24, 4551–4557 (2003).
25. Riegler J, Liew A, Hynes SO, Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials 34(8), 1987–94 (2013).
26. Rauch J, Kolch W, Laurent S, Mahmoudi M., Big signals from small particles: Regulation of cell signaling pathways by nanoparticles. Chem. Rev. 113, 3391–3406 (2013).
27. Luengo Y, Nardecchia S, Morales MP, Serrano MC. Different cell responses induced by exposure to maghemite nanoparticles. Nanoscale 5(23), 11428–11437 (2013).
28. Mahmoudi M, Quinlan-Pluck F, Monopoli MP, Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution. ACS Chem. Neurosci. 4(3), 475–485 (2013).
29. Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging 13(5), 675–691 (1995).
30. Zorko M, Langel Ü., Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 57, 529–545 (2005).
31. Wadia JS, Dowdy SF. Protein transduction technology. Curr. Opin. Biotechnol. 13, 52–56 (2002).
32. Zhao M, Kircher MF, Josephson L, Weissleder R., Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 13(4), 840–844 (2002).
33. Martin AL, Bernas LM, Rutt BK, Foster PJ, Gillies ER. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles functionalized with dendritic guanidines. Bioconjug. Chem. 19(12), 2375–2384 (2008).
34. Cavalli S, Carbajo D, Acosta M, Efficient γ-amino-proline-derived cell penetrating peptide–superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents. Chem. Commun. 48, 5322–5324 (2012).
35. Kondo E, Saito K, Tashiro Y, Tumour lineagehoming cell-penetrating peptides as anticancer molecular delivery systems. Nat. Commun. 3(951) (2012).
36. Svensen N, Walton JG, Bradley M., Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 33(4), 186–192 (2012).
37. Yamada T, Mehta RR, Lekmine F, A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol. Cancer Ther. 8(10), 2947–2958 (2009).
38. Warso MA, Richards JM, Mehta D, A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. J. Cancer 108(5), 1061–1070 (2013).
39. Reichert JM, Valge-Archer VE. Antibody cancer therapeutics. Nat. Rev. Drug Discov. 6, 349–356 (2007).
40. Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A, Jr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug. Chem. 13(1), 122–127 (2002).
41. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177–182 (1987).
42. Huh Y, Jun Y, Song H, In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. Chem. Soc. 127(35), 12387–12391 (2005).
43. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31(13), 3694–3706 (2010).
44. Vigor KL, Kyrtatos PG, Minogue S, Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 31(6), 1307–1315 (2010).
45. Piraux H, Hai J, Verbeke P, Transferrin receptor-1 iron-acquisition pathway – Synthesis, kinetics, thermodynamics and rapid cellular internalization of a holotransferrin-maghemite nanoparticle construct. Biochim. Biophys. Acta – Gen. Subj. 1830(8), 4254–4264 (2013).
46. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L., Nanoparticle imaging of integrins on tumor cells. Neoplasia 8(3), 214–222 (2006).
47. Xie J, Chen K, Lee H, Ultrasmall c(RGDyK)-coated Fe 3 O 4 nanoparticles and their specific targeting to integrin r v 3-rich tumor cells. J. Am. Chem. Soc. 130(24), 7542–7543 (2008).
48. Kizilel S, Nazli C, Ergenc Acar HY. RGDS-functionalized polyethylene glycol hydrogel-coated magnetic iron oxide nanoparticles enhance specific intracellular uptake by HeLa cells. Int. J. Nanomedicine 7, 1903–1920 (2012).
49. Lyons S, O'Neal J, Sontheimer H., Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 39, 162–173 (2002).
50. Sun C, Veiseh O, Gunn J, In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 4(3), 372–379 (2008).
51. Destouches D, El Khoury D, Hamma-Kourbali Y, Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One 3, e2518 (2008).
52. Destouches D, Page N, Hamma-Kourbali Y, A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer Res. 71(9), 3296–3305 (2011).
53. Chen T, Shukoor MI, Wang R, Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano 5(10), 7866–7873 (2011).
54. Sturge J, Wienke D, East L, Jones GE, Isacke CM. GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis. J. Cell Biol. 162(5), 789–794 (2003).
55. Moros M, Hernaez B, Garet E, Monosaccharides versus PEG-functionalized NPs: Influence in the cellular uptake. ACS Nano 6(2), 1565–1577 (2012).
56. Valero E, Tambalo S, Marzola P, Magnetic nanoparticles-templated assembly of protein subunits: A new platform for carbohydrate-based MRI nanoprobes. J. Am. Chem. Soc. 133(13), 4889–4895 (2011).
57. Weitman SD, Lark RH, Coney LR, Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52(12), 3396–3401 (1992).
58. Low PS, Henne W a, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41(1), 120–129 (2008).
59. Fan C, Gao W, Chen Z, Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles. Int. J. Pharm. 404(1–2), 180–190 (2011).
60. Sapsford KE, Algar WR, Berti L, Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology. Chem. Rev. 113(3), 1904–2074 (2013).
61. Almeida JP, Chen AL, Foster A, Drezek R., In vivo biodistribution of nanoparticles. Nanomedicine 6(5), 815–835 (2011).
62. Hillaireau H, Couvreur P., Nanocarriers' entry into the cell: Relevance to drug delivery. Cell. Mol. Life Sci. 66(17), 2873–2896 (2009).
63. Nel A, Xia T, Madler L, Li N., Toxic potential of materials at the nanolevel. Science 311(5761), 622–627 (2006).
64. Gupta AK, Curtis AS. Surface modified superparamagnetic nanoparticles for drug delivery: Interaction studies with human fibroblasts in culture. J Mater. Sci Mater. Med. 15(4), 493–496 (2004).
65. Singh N, Jenkins GJS, Asadi R, Doak SH. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 1 (2010).
66. Mahmoudi M, Simchi A, Imani M, Milani AS SP. An in vitro study of bare and poly(ethylene-glycol)-co-fumarate-coated superparamagnetic iron oxide nanoparticles: A new toxicity identification procedure. Nanotechnology 20(22), 225104 (2009).
67. Berry C, Wells S, Charles S, Aitchison G CA. Cell response to dextran-derivatised iron oxide nanoparticles post internalization. Biomaterials 25(23), 5405–5413 (2004).
68. Wu X, Tan Y, Mao H, Zhang M., Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int. J. Nanomedicine 5, 358–399 (2010).
69. Huang DM, Hsiao JK, Chen YC, The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. Biomaterials 30(22), 3645–3651 (2009).
70. Burton L, Berganos R, Shen B, Chin FT, Chen X, Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: A PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology 260(1), 182–191 (2011).
71. Lewinski N, Colvin V, Drezek R., Cytotoxicity of nanoparticles. Small 4, 26–49 (2008).
72. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat, Rev, Mol, Cell Biol. 7(3), 211–224 (2006).
73. Kim JS, Yoon TJ, Yu KN, Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol. Sci. 89(1), 338–347 (2006).
74. Yu M, Huang S, Yu KJ, Clyne AM. Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture. Int. J. Mol. Sci. 13(5), 5554–5570 (2012).
75. Anzai Y, Piccoli CW, Outwater EK, Radiology for the group evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study. Radiology 228(3), 777–788 (2003).
76. Gupta AK, Gupta M., Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995–4021 (2005).
77. Clemente-Casares X, Santamaria P., Nanomedicine in autoimmunity. Immunol Lett. 158(1–2), 167–174 (2014).
78. Richards JM, Shaw C, Lang NN, In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: Feasibility and safety in humans. Circ. Cardiovasc. Imaging 5(4), 509–517 (2012).
79. Maccioni F, Bruni A, Viscido A, MR imaging in patients with Crohn disease: Value of T2-versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology 238(2), 517–530 (2006).
80. D'Arienzo A, Scaglione G, Vicinanza G, Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis. Am. J. Gastroenterol. 95(3), 720–724 (2000).
81. D'Arienzo A, Scaglione G, Bennato R, The prognostic value, in active ulcerative colitis, of an increased intensity of colonic perivisceral fat signal on magnetic resonance imaging with ferumoxil. Am. J. Gastroenterol. 96(2), 481–486 (2001).
82. Gaglia JL, Guimaraes AR, Harisinghani M, Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J. Clin. Invest. 121(1), 442–445 (2010).
83. Vellinga MM, Vrenken H, Hulst HE, Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: An exploratory study. J. Magn. Reson. Imaging. 29, 774–779 (2009).
84. Tourdias T, Roggerone S, Filippi M, Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 264(1), 225–233 (2012).
85. Eitel I, Kubusch K, Strohm O, Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ. Cardiovasc. Imaging. 4(4), 354–362.
86. Payne AR, Berry C, Kellman P, Bright-blood T(2)-weighted MRI has high diagnostic accuracy for myocardial hemorrhage in myocardial infarction: A preclinical validation study in swine. Circ. Cardiovasc. Imaging 4(6), 738–745 (2011).
87. Yilmaz A, Dengler MA, van der Kuip H, Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur. Hear. J. 34(6), 462–475 (2012).
88. Sigovan M, Gasper W, Alley HF, Owens CD, Saloner D., USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 265(2), 584–590 (2012).
89. Degnan AJ, Patterson AJ, Tang TY, Howarth SP, Gillard JH. Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: Follow-up of the ATHEROMA trial. Cerebrovasc. Dis. 34(2), 169–173 (2012).
90. Ferguson PM, Feindel KW, Slocombe A, Strongly magnetic iron nanoparticles improve the diagnosis of small tumours in the reticuloendothelial system by magnetic resonance imaging. PLoS One 8, e56572 (2013).
91. Wu L, Cao Y, Liao C, Huang J, Gao F., Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: A meta-analysis. Eur. J. Radiol. 80(2), 582–589 (2010).
92. Harisinghani MG, Barentsz J, Hahn PF, Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491–2499 (2003).
93. Heesakkers RA, Hovels AM, Jager GJ, MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study. Lancet Oncol. 9(9), 850–856 (2008).
94. Ross RW, Zietman AL, Xie W, Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin. Imaging 33(4), 301–305 (2009).
95. Triantafyllou M, Studer UE, Birkhauser FD, Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur. J. Cancer 49(3), 616–624.
96. Johnson L, Pinder SE, Douek M., Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. Histopathology 62(3), 481–486 (2013).
97. Motomura K, Ishitobi M, Komoike Y, SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann. Surg. Oncol. 18(12), 3422–3429 (2011).
98. Motomura K, Izumi T, Tateishi S, Correlation between the area of high-signal intensity on SPIO-enhanced MR imaging and the pathologic size of sentinel node metastases in breast cancer patients with positive sentinel nodes. BMC Med. Imaging 13(32) (2013).
99. Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 71(4), 708–712 (2008).
100. Ferreira L, Karp JM, Nobre L, Langer R., New opportunities: The use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell 3(2), 136–146 (2008).
101. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S., Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. Neurol. 67(10), 1187–1194 (2010).
102. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat. Med. 10, 475–480 (2004).
103. De Vries IJ, Krooshoop DJ, Scharenborg NM, Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63(1), 12–17 (2003).
104. De Vries IJM, Lesterhuis WJ, Barentsz JO, Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23(11), 1407–1413 (2005).
105. Singh D, McMillan JM, Liu XM, Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine (Lond.) 9(3), 469–485 (2014).
106. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4(2), 386–393 (2009).
107. Vadhan-Raj S, Strauss W, Ford D, Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am. J. Hematol. 89(1), 7–12 (2014).
108. Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am. J. Hematol. 89(6), 646–650 (2014).
109. Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J., A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin. J. Am. Soc. Nephrol. 9(4), 705–712 (2014).
110. Hassan N, Cahill J, Rajasekaran S, Kovey K., Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: First case series. Ann. Pharmacother. 45(12), e63.
111. Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG. Magnetic nanoparticles: An emerging technology for malignant brain tumor imaging and therapy. Expert Rev. Clin. Pharmacol. 5(2), 173–186 (2012).
112. Hildebrandt B, Wust P, Ahlers O, The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 43(1), 33–56 (2002).
113. Wust P, Hildebrandt B, Sreenivasa G, Hyperthermia in combined treatment of cancer. Lancet Oncol. 3(8), 487–497 (2002).
114. Johannsen M, Gneveckow U, Taymoorian K, Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. Int. J. Hyperth. 23(3), 315–323 (2007).
115. Maier-Hauff K, Rothe R, Scholz R, Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. J. Neurooncol. 81(1), 53–60 (2007).
116. Maier-Hauff K, Ulrich F, Nestler D, Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103(2), 317–324 (2011).
117. Matsumine A, Takegami K, Asanuma K, A novel hyperthermia treatment for bone metastases using magnetic materials. Int. J. Clin. Oncol. 16(2), 101–108 (2011).
118. Mamiya H., Recent advances in understanding magnetic nanoparticles in AC magnetic fields and optimal design for targeted hyperthermia. Journal of Nanomaterials vol. 2013 (2013).
119. Zhang E., Kircher M. F., Koch M., Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation. ACS Nano 8(4), 3192–3201 (2014).
120. Riedinger A., Guardia P., Curcio A., Subnanometer local temperature probing and remotely controlled drug release based on azo*functionalized iron oxide nanoparticles, Nano Lett. 13(6), 2399–2406 (2013).
121. Kunisaki J., Saito T., Yamada T., A possibility of hyperthermia using MRI equipment. Conf. Proc. IEEE Eng. Med. Biol. Soc. 1, 6373–6375 (2006).
122. Cantillon-Murphy P., Wald L. L., Zahn M., Adalsteinsson E., Proposing magnetic nanoparticle hyperthermia in low-field MRI. Concepts in Magnetic Resonance Part A 36A(1), 36–47 (2010).
123. Jiles D., Intzroduction to Magnetism and Magnetic materials. CRC Press.
124. Coey JMD. Magnetism and Magnetic Materials. Cambridge University Press. 2009.
125. Thanh NT. Magnetic Nanoparticles: From Fabrication to Medical and Clinical Applications. CRC Press. 2011.
126. Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nat. Mater. 13(2), 125–138 (2014).